Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsDrreddyslaboratories

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Dr Reddy's Labs can retest Rs 2995-3000: Hemant Thukral

      Hemant Thukral of Aditya Birla Money is of the view that Dr Reddy's Laboratories can retest Rs 2995-3000.

    • See upside in Dr Reddy's Laboratories: Amit Gupta

      According to Amit Gupta of ICICIdirect, Dr Reddy's Laboratories should move up.

    • Buy Dr Reddy's Labs 3000 Call, sell 3100 Call: Subramanyam

      Krish Subramanyam of Asit C.Mehta Investment Intermediates is of the view that one can buy Dr Reddy's Laboratories 3000 Call and sell 3100 Call.

    • Mahantesh Sabarad overweight on pharma, prefers Dr Reddy's

      Mahantesh Sabarad, Deputy Head of Research at SBI Capital Securities has a overweight stance on pharma space and prefers Dr Reddy's Laboratories.

    • Satish Ramanathan positive on pharma sector

      Satish Ramanathan, Market Analyst has a positive view on the pharma sector.

    • Jyotivardhan Jaipuria neutral on pharma space

      Jyotivardhan Jaipuria, Head of Research, BofA ML is neutral on pharma space.

    • Buy Dr Reddy‘s Laboratories: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may buy Dr Reddy‘s Laboratories.

    • Nilesh Shah cautious on pharma sector

      Nilesh Shah, MD & CEO of Envision Capital is cautious on the pharmaceutical sector.

    • Buy Dr Reddy's Laboratories, advises Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Dr Reddy's Laboratories.

    • Buy Dr Reddy's Laboratories on declines: Amit Gupta

      Amit Gupta of ICICIdirect recommends buying Dr Reddy's Laboratories on declines and expects the stock to go beyond Rs 3000.

    • Buy Dr Reddy's Labs, TCS, Apollo Hospitals: Mayuresh Joshi

      Mayuresh Joshi, VP- Institution at Angel Broking recommends buying Dr Reddy's Laboratories, Tata Consultancy Services and Apollo Hospitals Enterprises.

    • Buy ONGC, Infosys, Dr Reddy's Laboratories: Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Oil and Natural Gas Corporation, Dr Reddys Laboratories and Infosys.

    • Your Stocks: Recommendations by experts

      Watch the interview of Mayuresh Joshi, VP- Institution at Angel Broking Ltd and Kunal Saraogi, CEO of Equityrush with Sumaira Abidi & Latha Venkatesh on CNBC-TV18, in which they both shared their reading and outlook on market and specific stocks.

    • Go long in Dr Reddy‘s Laboratories: Ashish Chaturmohta

      Ashish Chaturmohta of Fortune Equity Broker recommends going long in Dr Reddy‘s Laboratories at current levels.

    • Prefer Cipla, Sun Pharma, Dr Reddys: Phani Sekhar

      According to Phani Sekhar of Angel Broking, one may prefer Cipla, Sun Pharmaceuticals and Dr Reddy‘s Laboratories in pharma space.

    • Top 10 stocks to focus on March 10

      According to CNBC-TV18‘s research team following are the stocks to focus on Dr Reddy's, BPCL, Ranbaxy, Dishman Pharma, Bank of Baroda, Ashok Leyland, Jaiprakash Assoc, Crompton Greaves, Eicher Motors and Infotech Ent.

    • Top 10 stocks: Keep an eye on ICICI Bank, Infosys, DRL

      The top 10 stocks identified by the CNBC-TV18 research team to watch out for today are ICICI Bank, Infosys, Dr Reddy‘s , Glenmark, Ashok Leyland, HeroMoto Corp, Maruti, Jaiprakash Power, HCC, and Elantas Beck

    • Expiry day: Top 10 stocks for today

      Here are the top 10 stocks that are expected to show smart moves today.

    • Dipan Mehta positive on pharma stocks

      Dipan Mehta, Member of BSE & NSE is positive on pharma companies with a medium to long term perspective.

    • Dr Reddys Laboratories may test Rs 3023: Ajay Bodke

      According to Ajay Bodke, head-investment strategy & advisory at Prabhudas Lilladher, Dr Reddys Laboratories may test Rs 3023 in one year period.

    • Go long in Dr Reddys Laboratories: Amit Gupta

      According to Amit Gupta, head- derivatives at ICICI Direct, one may go long in Dr Reddys Laboratories at around Rs 2600-2650 and expects it to test Rs 2750.

    • Prefer IT, pharma stocks: Nirmal Jain

      Nirmal Jain, Chairman at IIFL prefers IT and pharma sector.

    • Positive on Dr Reddy's Labs: SP Tulsian

      SP Tulsian of sptulsian.com is of the view that one may pick Dr Reddy's Laboratories on correction.

    • Super Six short term picks for February 11

      Vishal B Malkan of malkansview.com suggests buying Dr Reddys Laboratories with a target of Rs 2740-2760 and Sun Pharmaceutical Industries with a target of Rs 625-635.

    • Buy Dr Reddys Laboratories 2700 Call: Bhavin Desai

      Bhavin Desai of Motilal Oswal Securities recommends going long in Dr Reddys Laboratories 2700 Call with a target of Rs 90.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347